• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content

Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Like this document? Why not share!

CancerStoryExperts.doc

on

  • 275 views

 

Statistics

Views

Total Views
275
Views on SlideShare
275
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft Word

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    CancerStoryExperts.doc CancerStoryExperts.doc Document Transcript

    • CancerStory Experts Part 1 - What Is Cancer C. Norman Coleman, MD C. Norman Coleman, MD, is director of the Radiation Oncology Sciences Program for the National Cancer Institute in Bethesda, Md. He also serves the NCI as chief of the Radiation Oncology Branch and deputy director of the Center for Cancer Research, among other positions. He earned his bachelor’s degree from the University of Vermont and medical degree from Yale. He completed his internship and residency at the University of California in San Francisco and at the NCI. He served on the staff of Stanford University’s School of Medicine before joining Harvard Medical School in 1985. He joined the NCI in 1999. He is the author of “Understanding Cancer: A Patient’s Guide to Diagnosis, Prognosis and Treatment,” published in 1998. Andrew C. Von Eschenbach, MD Andrew C. Von Eschenbach, MD, was named director of the National Cancer Institute in December 2001. Previously, he was a research director at the University of Texas M.D. Anderson Cancer Center. A urologist by training and a cancer survivor himself, he earned his bachelor’s degree from St. Joseph’s University in Philadelphia, and his medical degree from Georgetown University Medical School. He completed residencies at Pennsylvania Hospital in Philadelphia before becoming an instructor in urology at the University of Pennsylvania Medical School. Mark A. Israel, MD Mark A. Israel, MD, since October 2001 has been director of the Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center in Lebanon, N.H. Previously, he was the Kathleen M. Plant Distinguished Professor and Director of the Preuss Laboratory of Molecular Neuro-Oncology at University of California at San Francisco, where he had been a faculty member since 1990. A leading expert on childhood brain tumors, Israel graduated from Hamilton College and the Albert Einstein College of Medicine. Following his training in pediatrics at the Children's Hospital Medical Center in Boston, he was recruited to the National Institutes of Health, where he rose to head the Molecular Biology Section (formerly molecular genetics) in the Pediatric Branch of the National Cancer Institute. Christopher H. Lowrey, MD Christopher H. Lowrey, MD, is acting section chief of the Section of Hematology/Oncology of the Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center. He joined the faculty of Dartmouth Medical School in 1993, and has been co-director of the Hem/Onc Fellowship Program in charge of research since 1996. He earned his bachelor’s degree from Bowdoin College, his master’s from the University of Pennsylvania, and his medical degree from Boston University. He completed his residency at the New England Medical Center and the National Institutes of Health. Part 2 - Voices Julia Rowland, PhD Julia Rowland, PhD, was appointed director of NCI’s Office of Cancer Survivorship in September 1999. Before coming to DCCPS, she was the founding director of the Psycho- Oncology Program at the Lombardi Cancer Center at Georgetown University (1990-1999). Prior to that, she trained and worked for 13 years in psycho-oncology at Memorial Sloan-Kettering Cancer Center (MSKCC). Dr. Rowland received her PhD in developmental psychology from
    • Columbia University in 1984 and was one of the first two post-doctoral fellows at MSKCC to receive NIH-supported training in the then newly-emergent field of psychosocial oncology. While at MSKCC, where she held joint appointments in pediatrics and neurology, Dr. Rowland helped establish and was the first director of the Post-treatment Resource Program. Her research has focused on both pediatric and adult cancer survivorship. She has published extensively on women’s reactions to breast cancer, as well as on the roles of coping, social support, and developmental stage in a patient’s adaptation to cancer. She co-edited the groundbreaking text, Handbook of Psychooncology: Psychological Care of the Patient with Cancer (1989), and is the author of more than 75 scientific articles, reviews, and book chapters. Lisa A. Szczepaniak, ARNP, MSN Lisa A. Szczepaniak, ARNP, MSN, is Director of Clinical Services, Palliative Medicine at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire. She earned her masters in science of nursing degree from Kent State University in Ohio and her nurse practitioner degree at the University Hospitals of Cleveland. Part 3 - New Directions O. Ross McIntyre, MD Dr. McIntyre was director of Norris Cotton Cancer Center in New Hampshire from 1975-1992. As chair of the Cancer and Leukemia Group B, he assisted in the early development of cancer treatment trials. He is a graduate of Dartmouth College, Dartmouth Medical School, and Harvard Medical School. His work for the last several years has focused on the design, implementation, and analysis of large cancer treatment trials with particular emphasis on leukemia and multiple myeloma. He maintains an interest in cancer epidemiology, screening and prevention, and psychosocial studies in cancer. Richard Stone, MD Dr. Stone is clinical director, Adult Acute Leukemia Program at the Dana-Farber Cancer Institute (DFCI) and associate professor of medicine at Harvard Medical School. He received his MD in 1981 from Harvard Medical School, his internal medicine residency training at Brigham and Women's Hospital, and his hematology-oncology fellowship at DFCI. He has performed numerous laboratory and clinical studies on acute leukemia and related disorders, and frequently participates in grand rounds worldwide. He is currently the clinical director of the Adult Acute Leukemia Program at DFCI and is vice chair of the Leukemia Core Committee for the national cooperative trials group Cancer and Leukemia Group B. Gary Gilliland, PhD, MD Dr. Gilliland studies the genetics and pathophysiology of human hematologic malignancies, with the goal of translating these findings into improved outcomes for patients. He is professor of medicine at Brigham and Women's Hospital and Harvard Medical School; a member of the faculty of the department of Genetics in the graduate school of Biomedical and Biological Sciences, also at Harvard Medical School; director of the Leukemia Program at the Dana-Farber/ Harvard Cancer Center; and attending physician at Brigham and Women's Hospital and the Dana- Farber Cancer Institute. He is a residential member of the Harvard Institute of Human Genetics. Dr. Gilliland received his Ph.D. degree in microbiology at the University of California, Los Angeles, under the mentorship of R. John Collier, and his M.D. degree from the University of California, San Francisco. He trained in internal medicine and was chief medical resident at Brigham and Women's Hospital. His fellowship training in hematology and oncology was done at Brigham and Women's Hospital and the Dana-Farber Cancer Institute.
    • Richard J. Barth Jr. MD Dr. Barth is associate professor of surgery at Dartmouth Medical School and section chief for general surgery at Dartmouth-Hitchcock Medical Center. Among his clinical interests are surgical oncology and immunotherapy for colon and rectal cancer. Dr. Barth received an A.B. in Biochemical Sciences from Princeton in 1981, and an M.D. from Harvard Medical School in 1985. During the middle of his surgical residency at the New England Deaconess Hospital, he spent 2.5 years in the laboratory of Dr. Steven Rosenberg at the National Cancer Institute. Dr. Barth joined the faculty of Dartmouth Medical School in 1993. Dr. Barth's lab is investigating the immune response to tumors to develop more effective vaccines. Eric C. Larsen, MD Eric C. Larsen, MD, is director of the Division of Pediatric Hematology-Oncology at Dartmouth- Hitchcock Medical Center and a member of the Immunology and Cancer Immunotherapy Research Program at Norris Cotton Cancer Center in Lebanon, NH. He is Associate Professor of Pediatrics at Dartmouth Medial School, having joined the faculty in 1990. He earned his bachelor’s degree at Harvard College and his medical degree from the University of Vermont College of Medicine. Randy Noelle, PhD Dr. Noelle is professor of microbiology and immunology at Dartmouth Medical School and deputy director of the Norris Cotton Cancer Center, as well as co-director of the center’s Immunology and Cancer Immunotherapy Research Program. Dr. Noelle was a post-doctoral fellow at the University of Texas Health Science Center at Dallas from 1980-1984, and in 1984, he joined the faculty of Dartmouth Medical School as an Assistant Professor. In 1995, he was promoted to Professor of Microbiology. Dr. Noelle's laboratory has identified a novel membrane protein expressed on helper T lymphocytes (Th), CD154. Research is focused on how to block a wide spectrum of immune and autoimmune responses and transplantation rejection. Daphne Haas-Kogan, MD Dr. Daphne A. Haas-Kogan is assistant professor of Radiation Oncology at the University of California San Francisco and a radiation oncologist at the UCSF Comprehensive Cancer Center. She is an expert in the treatment of pediatric cancers. In addition to caring for patients, she is an accomplished scientist who investigates the effects of radiation therapy on cancer tumors. Her work on this subject has been published widely in medical and science journals. Haas-Kogan, a recipient of numerous awards, completed her medical degree and residency in radiation oncology at the University of California, San Francisco. She is an assistant professor in radiation oncology at UCSF. Edward A. Sausville, MD, PhD Edward A. Sausville, M.D., Ph.D is the associate director of clinical research at the University of Maryland Greenebaum Cancer Center and a faculty member of the University of Maryland School of Medicine. Dr. Sausville was previously associate director of the National Cancer Institute’s Developmental Therapeutics Program, which played a key role in developing many of the new cancer drugs in use today. Dr. Sausville received his M.D. and a Ph.D. in Pharmacology from the Albert Einstein College of Medicine in the Bronx, N.Y., in the late 1970s. He completed his residency at Brigham & Women’s Hospital in Boston in 1982 and a three-year fellowship in the clinical oncology program at the National Cancer Institute in 1985. He then was an attending physician at the U.S. Naval Hospital in Bethesda and Georgetown University Hospital in Washington before returning to the National Cancer Institute in 1990. He has served as associate director of NCI’s Developmental Therapeutics Program since 1994. The Developmental Therapeutics Program is involved in all aspects of drug development from the initial discovery of
    • an agent in a basic research laboratory to wide-scale testing in a national clinical trial. NCI collaborates with government laboratories, research institutes, academic institutions and companies throughout the world in its search for new compounds. Alan H. Siegel, MD Alan H. Siegel, MD is Director of Nuclear Medicine at Dartmouth-Hitchcock Medical Center and is Associate Professor of Radiology at Dartmouth Medical School. He received his bachelors degree from Haverford College in Haverford, PA and his medical degree from Mount Sinai Medical School in New York. Dr. Siegel completed his residency at Beth Israel Medial Center in New York and did a fellowship in Nuclear Medicine at the University of Pennsylvania. Part 4 - Prevention and Screening Otis W. Brawley , MD Dr. Otis W. Brawley is professor of medicine of Hematology and Oncology at the Emory University School of Medicine and professor of Epidemiology at the Emory Rollins School of Public Health. He also serves as associate director of the Winship Cancer Institute at Emory University and as director of the Georgia Cancer Center of Excellence at Grady. Dr. Brawley's interest in the dissemination of medical knowledge has extended to ethical issues and the availability of new knowledge and technologies to socio-economically disadvantaged communities. His work concerning racial differences in patterns of medical care and the similar outcomes among racial and ethnic groups when there is equal treatment is widely cited in medical literature. Prior to Emory, Brawley was assistant director at the National Cancer Institute for its Office of Special Populations Research. He held an appointment in the Division of Cancer Prevention and was an attending physician at Bethesda Naval Hospital and the National Institutes of Health Clinical Center. Neil Benowtiz, MD Dr. Benowitz, a professor of medicine, psychiatry, and pharmacy at the University of California at San Francisco, is one of the world's experts on the effects of nicotine and how it is broken down in the blood and removed from the body. His research has helped explain the addictive nature of nicotine and tobacco and the role nicotine and other substances in tobacco smoke play in various diseases. Dr. Benowitz began studying nicotine and its effects on people in 1975 when that area of research was in its infancy. His early investigations showed how nicotine behaves in the blood and how it is metabolized or broken down by the body. Dr. Benowitz's research has influenced policy and treatment strategies. For example, his research on nicotine addiction among young people contributed to greater restrictions on smoking in schools. Robert A. Smith, PhD Robert Smith is a cancer epidemiologist and director of Cancer Screening at the National Office of the American Cancer Society (ACS) in Atlanta, Georgia. He also is adjunct professor of Epidemiology at the Emory School of Public Health. Prior to joining the staff at the ACS, he held positions with the Centers for Disease Control and the Boston University School of Public Health. He has served on many national and federal advisory committees and working groups, and is the co-chair of the National Colorectal Cancer Roundtable. Currently, he serves on the Center for Medicare and Medicaid Services Breast Cancer Expert Group, the Centers for Disease Control's Breast and Cervical Cancer Early Detection and Control Advisory Committee, and he is
    • chair of the Data Safety and Monitoring Committee for the Digital Mammography Trial. In 1995, he was made an Honorary Fellow of the Society of Breast Imaging. Peter Greenwald, MD, Dr. PH Dr. Greenwald is director of the Division of Cancer Prevention and Control at the National Cancer lnstitute, NIH. Before assuming that position in 1981, he was director of the Cancer Control Bureau, NY State Department of Health; director of the Epidemiology and Disease Control Study Section, of the NIH, and director of the Division of Epidemiology, NYS Dept. of Health. Bruce Ames, PhD Dr. Ames is a professor of Biochemistry and Molecular Biology, University of California, Berkeley , and a senior scientist at Children's Hospital Oakland Research Institute (CHORI). Among other things, he is the discoverer of the Ames Test, used to detect and determine carcinogens. He is a member of the National Academy of Sciences and was on their Commission on Life Sciences. He was a member of the board of directors of the National Cancer Institute, the National Cancer Advisory Board, from 1976 to 1982. He was the recipient of the General Motors Cancer Research Foundation Prize (1983), the Tyler Environmental Prize (1985), the Gold Medal Award of the American Institute of Chemists (1991), the Glenn Foundation Award of the Gerontological Society of America (1992), the Lovelace Institutes Award for Excellence in Environmental Health Research (1995), the Honda Prize of the Honda Foundation, Japan (1996), the Japan Prize, (1997), the Kehoe Award, American College of Occup. and Environ. Med. (1997), the Medal of the City of Paris (1998), the U.S. National Medal of Science (1998), The Linus Pauling Institute Prize for Health Research (2001), and the American Society for Microbiology Lifetime Achievement Award (2001). His over 450 publications have resulted in his being among the few hundred most-cited scientists (in all fields). Ross Hammond Ross Hammond is an independent consultant based in San Francisco, and an internationally recognized expert in tobacco control. His focus is on the international dimensions of the tobacco epidemic. He has a masters degree in Applied Economics from American University. He is closely associated with the Campaign for Tobacco Free Kids. Before coming to tobacco control, he worked on a number of different international issues, from the reform of the international financial institutions, to the refugees’ crisis in the Horn of Africa, to the role of NGOs in international advocacy. Over the past 15 years he has worked in East Africa, Washington, DC and at UN headquarters in New York. Lynn Butterly, MD Dr. Butterly is a gastroenterologist at Dartmouth-Hitchcock Medical Center and an associate professor of medicine at Dartmouth Medical School. She has a special interest in colon cancer, risk assessment for colorectal cancer, and screening for colorectal cancer or polyps. She is well known for her promotion of education for colon cancer screening. Dr. Butterly is a graduate of Harvard Medical School and has held teaching appointments at Harvard Medical School, Tufts University School of Medicine, and currently at Dartmouth Medical School.